White & Case Advises Managers on Hansa Biopharma's SEK 1.112 Billion Directed Share Issue

Global law firm White & Case LLP has advised Morgan Stanley & Co International plc, Van Lanschot Kempen Wealth Management N.V. and Zonda Partners AB on the directed share issue by Hansa Biopharma.

The Hansa Biopharma board of directors agreed the directed share issue of 4,447,345 new shares at a subscription price of SEK 250 per share on July 8, 2020. The company will receive gross proceeds of approximately SEK 1.112 billion (approximately US$121 million). The subscription price was determined through an accelerated bookbuilding process.

Established in 2007 and based in Lund, Sweden, Hansa Biopharma is leveraging its proprietary immunomodulatory enzyme technology platform to develop treatments for rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection and cancer.

The White & Case team which advised on the transaction was led by partner Rikard Stenberg (Stockholm) and included partner Mikko Hulkko (Helsinki) and associate Christoffer Nilmén (Stockholm).

Press contact
For more information, please speak to your local media contact.